F

    Foghorn Therapeutics Inc (FHTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.74
    -0.26 (-4.33%)

    Market Cap: $356.31M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(10/25)
    Avg Surprise
    -14.16%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.24
    Range$-0.32 - $-0.15
    7 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.24+0.0%
    60d ago$-0.24+0.0%
    30d ago$-0.24+0.0%
    7d ago$-0.24+0.0%
    Current$-0.24
    Revenue Consensus
    $8M
    Range$3M - $12M
    9 analysts
    Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.35 - $0.13
    7 analysts
    Revenue Consensus
    $10M
    Range$-4639760 - $20M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.24---
    Jun 26
    		$-0.10N/A+56.52%Beat+64.3%
    Mar 26
    		$-0.29$-0.31+6.45%Beat+3.3%
    Dec 25
    		$-0.37$-0.26-41.14%Miss-21.8%
    Sep 25
    		$-0.25$-0.31+19.35%Beat+19.4%
    Jun 25
    		$-0.28$-0.32+12.50%Beat+37.8%
    Mar 25
    		$-0.30$-0.29-3.45%Miss+49.2%
    Dec 24
    		$-0.30$-0.28-7.14%Miss+47.4%
    Sep 24
    		$-0.31$-0.43+27.91%Beat+8.8%
    Jun 24
    		$-0.45$-0.64+29.69%Beat+35.7%
    Mar 24
    		$-0.59$-0.59+0.00%Beat+19.2%
    Dec 23
    		$-0.57$-0.76+25.00%Beat+17.4%
    Sep 23
    		$-0.34$-0.65+47.69%Beat+45.2%
    Jun 23
    		$-0.70$-0.69-1.45%Miss-6.1%
    Mar 23
    		$-0.73$-0.72-1.39%Miss-12.3%
    Dec 22
    		$-0.69$-0.54-27.78%Miss+6.8%
    Sep 22
    		$-0.62$-0.50-24.00%Miss+12.7%
    Jun 22
    		$-0.66$-0.41-60.98%Miss-4.8%
    Mar 22
    		$-0.65$-0.47-38.30%Miss-4.8%
    Dec 21
    		$-0.74$-0.49-51.02%Miss+60.2%
    Sep 21
    		$-0.71$-0.59-20.34%Miss+77.2%
    Jun 21
    		$-0.63$-0.59-6.78%Miss+51.2%
    Mar 21
    		$-0.62$-0.55-12.73%Miss-
    Dec 20
    		$-1.86$-0.45-313.33%Miss-
    Sep 20
    		$-3.12$-2.69-15.99%Miss-
    Jun 20
    		$-1.29$-2.42+46.69%Beat-

    Key Metrics

    Valuation
    P/E Ratio-5.71EV/EBITDA-1.21x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-175.80%Operating Margin-54.80%
    ROE-470.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.36xQuick Ratio3.36x
    Trading Statistics
    Beta2.83Avg Volume344.52K
    52-Week High$7.6152-Week Low$3.27

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.63
    SMA 20$6.33
    SMA 50$5.55
    SMA 200$5.10
    EMA 10$6.36
    EMA 20$6.23
    EMA 50$5.69
    EMA 200$5.11

    MACD

    Line: 0.26Signal: 0.39Hist: -0.14

    ADX

    ADX: 27.7+DI: 21.9-DI: 25.9

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down16.0
    PSAR$7.43

    Bollinger Bands

    Upper Band$7.64
    Lower Band$5.02
    %B Position4141%(Upper)
    Band Width0.27

    RSI (14-Day)

    Neutral
    43.8

    Momentum Oscillators

    Stoch %K6.5
    Stoch %D26.3
    Williams %R-99.2
    ROC (10d)-14.8%
    Momentum-1.00
    CCI (20d)-67.1
    MFI (14d)50.4

    Volatility Measures

    ATR (14d)$0.46(7.9%)
    StdDev (20d)0.66
    Hist Vol82.5%(High)

    Volume Flow

    VWAP$5.81
    OBV3.7M
    AD Line-2.6M
    CMF (20d)-0.202

    Volume Metrics

    Avg Vol (20d)351.0K
    Vol Ratio0.9x
    VWMA (20d)$6.50

    Pivot Points

    R3$6.45
    R2$6.35
    R1$6.17
    Pivot Point$6.07
    S1$5.89
    S2$5.79
    S3$5.61

    Advanced Oscillators

    TSI18.37
    Ultimate Osc31.4
    KST268.94

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$16.07M$3.27M$9.25M$8.15M$7.56M$5.95M$2.86M$7.81M$6.89M$5.05M$5.77M$17.48M
    Cost of Revenue$0$0$802,000$0$0$0$761,000$0$0$0$852,000$0
    Gross Profit$16.07M$3.27M$9.25M$8.15M$7.56M$5.95M$2.86M$7.81M$6.89M$5.05M$5.77M$17.48M
    Operating Expenses$24.88M$24.84M$33.13M$26.65M$28.65M$28.86M$26.86M$31.66M$33.52M$33.24M$31.23M$34.56M
    R&D$18.52M$18.26M$22.05M$20.00M$21.79M$21.63M$20.51M$24.69M$23.80M$25.53M$24.20M$26.25M
    SG&A$6.35M$6.58M$6.80M$6.65M$6.86M$7.24M$6.35M$6.97M$7.33M$7.71M$7.02M$8.31M
    Operating Income$-8,805,000$-21,573,000$-23,878,000$-18,501,000$-21,097,000$-22,913,000$-24,005,000$-23,852,000$-26,632,000$-28,194,000$-25,458,000$-17,081,000
    Interest Income$1.61M$1.74M$1.71M$2.03M$2.31M$2.69M$3.10M$3.50M$2.87M$2.44M$2.66M$2.75M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-7,191,000$-19,875,000$-21,664,000$-15,849,000$-17,936,000$-18,834,000$-19,503,000$-19,122,000$-22,979,000$-25,016,000$-22,120,000$-13,607,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$1.99M$738,000
    Net Income$-7,191,000$-19,875,000$-21,664,000$-15,849,000$-17,936,000$-18,834,000$-19,503,000$-19,122,000$-22,979,000$-25,016,000$-24,106,000$-14,345,000
    EBITDA$-9,193,000$-21,767,000$-22,880,000$-17,385,000$-19,840,000$-21,517,000$-23,407,000$-23,669,000$-25,763,000$-27,174,000$-24,423,000$-16,151,000
    EBIT$-8,805,000$-21,617,000$-23,376,000$-17,881,000$-20,245,000$-21,526,000$-22,599,000$-22,617,000$-25,849,000$-27,455,000$-24,780,000$-16,360,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FHTX

    News

    Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12

    Stifel reiterated a Buy rating on Foghorn Therapeutics Inc. (NASDAQ:FHTX) with a $12.00 price target, suggesting a potential upside of over 90%. The firm justifies this premium valuation due to Foghorn's partnership with Eli Lilly, its degrader pipeline, and a cash runway extending into the first half of 2028. Stifel believes a positive update for FHD-909 in mid-2026 could validate the platform and support a high takeout valuation.

    Investing.com•8/17/26•
    Bullish

    Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

    Foghorn Therapeutics Inc. (FHTX) is presented as a strong momentum stock due to its positive price performance and favorable earnings estimate revisions, aligning with its Zacks Rank #2 (Buy) and a Momentum Style Score of B. The article highlights FHTX's significant outperformance compared to its industry and the broader S&P 500 over various timeframes, coupled with upward revisions in its earnings estimates. Investors are encouraged to consider FHTX for potential short-term gains based on these indicators.

    Yahoo Finance•8/14/26•
    Bullish

    News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts

    Analysts have significantly upgraded their forecasts for Foghorn Therapeutics Inc. (NASDAQ:FHTX), increasing revenue estimates and reducing projected losses for the current year. Following these revisions, the company is now expected to generate US$34 million in revenue, a 6.9% decline from the previous year, with losses narrowing to US$0.85 per share. Despite the positive adjustments, Foghorn Therapeutics' projected revenue decline of 13% annually is still expected to underperform the broader industry's anticipated 23% annual growth.

    Sahm•8/13/26•
    Bullish

    News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts

    Analysts have significantly upgraded their forecasts for Foghorn Therapeutics Inc. (NASDAQ:FHTX) for the current year, increasing revenue estimates to US$34m and reducing loss per share predictions to US$0.85. This positive sentiment follows a 36% rise in the stock price over the past week. Despite the upgrades, the company's revenue growth is still expected to underperform the broader biotech industry.

    Simply Wall Street•8/12/26•
    Somewhat-Bullish

    Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX

    This article focuses on the enterprise value to EBIT forward for Foghorn Therapeutics Inc. (NASDAQ: FHTX). It appears to be a financial data point provided by TradingView, although no specific financial figures are included in the content itself. The article's main purpose is to present this financial metric for the specified company.

    TradingView•8/12/26•
    Neutral

    Frequently Asked Questions About FHTX

    Does FHTX pay dividends?
    Foghorn Therapeutics Inc (FHTX) does not currently pay a regular dividend.
    What is FHTX's market cap?
    Foghorn Therapeutics Inc (FHTX) has a market capitalization of $356.31M with a current stock price of $5.74.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In